Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of intraperitoneal cefepime in APD patients without peritonitis
2023-509930-21-00Phase 4Completed
- Sponsor
- NÖ Landesgesundheitsagentur
- Start
- Apr 2024
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cefepime in bacterial disease, sponsored by NÖ Landesgesundheitsagentur. Primary endpoints: AUC, Cmax and 2 more. Started Apr 2024; status: completed.
02
Drugs
cefepime
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2023-509930-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509930-21-00.